FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Thomsen Jillian B.						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]									tionship of Reportir all applicable) Director Officer (give title		son(s) to Iss 10% O Other (s	ner
	KTAR THE	rirst) RAPEUTICS BOULEVARD	(Middle)			Date o /28/2		iest Trans	saction (M	Month	/Day/Year)		X below) SVP &		below) ccounting Officer		cer	
(Street) SAN FRANCE	ISCO C	A	94158		4.1	Line) X Form fil									loint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting			
(City)	(S	state)	(Zip)															
		Tab	le I - No	n-Deriv	vativ	e Se	curit	ties Ac	quired	, Di	sposed o	f, or Be	neficial	ly Owned	I			
1. Title of Security (Instr. 3) 2. TransDate (Month/I				Execution Date,		Transaction Disposed (ies Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(1130.4)
Common Stock ⁽¹⁾ 01/28				01/28	/2021	2021			М		37,500	A	\$8.8	213	,757 ⁽²⁾		D	
Common Stock ⁽¹⁾ 01/28/				/2021	2021		М		37,500	A	\$8.8	251	,257 ⁽²⁾		D			
Common Stock ⁽¹⁾ 01/28/2				/2021	2021		S		75,000	D	\$18.62	⁽³⁾ 176	176,257 ⁽²⁾		D			
		-	Table II -								osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,		ansaction ode (Instr.		n of		Exerci on Da Day/Y		7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g e Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e Over Section Ove	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Stock Option ⁽¹⁾	\$8.8	01/28/2021			М			37,500	02/06/20	017	02/05/2021	Common Stock	37,500	\$0.00	0		D	

Explanation of Responses:

\$8.8

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021.
- 2. This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

37,500

3. This transaction was executed in multiple trades at prices ranging from \$18.26 to \$19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

02/06/2017

02/05/2021

Remarks:

 ${\bf Option^{(1)}}$

Mark A. Wilson, Attorney-in-01/29/2021 **Fact**

** Signature of Reporting Person Date

37,500

\$0.00

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/28/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.